Ostomy Readmission Reduction Program
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yosef Nasseri, MD
- Phone Number: 310-289-1518
- Email: Yosef.Nasseri@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Surgery Group LA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Elective operations involving an ileostomy or a colostomy
- Individuals 18 years old or older are included
Exclusion Criteria:
- Individuals under age 18
- Pregnant patients
- Emergency operations
- Patients with existing pre operative ostomies
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Readmission to hospital within 30 Days of Surgery
Time Frame: 30 Days Post Surgery
|
The proportion of participants who are readmitted to the hospital within 30 days following surgery.
Readmissions will be evaluated for any reason, including complications, adverse events, or recovery issues that necessitate hospitalization after the initial surgical procedure.
|
30 Days Post Surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital Length of Stay
Time Frame: From index surgery to discharge (up to 30 days postoperatively)
|
Total duration of hospitalization from the time of the index surgery until discharge.
|
From index surgery to discharge (up to 30 days postoperatively)
|
|
Incidence of Acute Kidney Injury (AKI)
Time Frame: From index surgery through 30 days postoperatively
|
Number of participants who develop AKI, defined as an increase in serum creatinine of ≥0.3 mg/dL from baseline, during index admission or upon 30-day readmission.
|
From index surgery through 30 days postoperatively
|
|
Incidence of Peristomal Skin Complications
Time Frame: From index surgery through 30 days postoperatively
|
Number of participants who develop peristomal skin problems (e.g., irritation, excoriation, or dermatitis) during the index admission or within 30 days postoperatively.
|
From index surgery through 30 days postoperatively
|
|
Incidence of Stoma-Related Leakage
Time Frame: From index surgery through 30 days postoperatively
|
Number of participants who experience unintended escape of stoma output (leakage) during index admission or within 30 days postoperatively.
|
From index surgery through 30 days postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yosef Nasseri, MD, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- STUDY00003920
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.